Results 131 to 140 of about 70,632 (264)

Low serum transferrin predicts adverse outcome in COVID‐19 and is related to coagulation activity

British Journal of Haematology, EarlyView.
Lukas Lanser, Francesco Robert Burkert, Lis Thommes, Rosa Bellmann‐Weiler, Guenter Weiss   +4 more
wiley   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Associations of obesity, systemic inflammation, and hyperinsulinemia with the incidence of non‐communicable chronic disease and mortality: A prospective cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity, systemic inflammation, and hyperinsulinemia are all features of metabolic syndrome and frequently occur together. We aimed to evaluate the association of body mass index (BMI) with incident non‐communicable chronic disease (NCD) or all‐cause mortality, independent of C‐reactive protein (CRP) and fasting insulin.
Natasha Wiebe, Stephanie Thompson, Peter Stenvinkel, Aminu Bello, Matthew T. James, Marcello Tonelli   +5 more
wiley   +1 more source

Associations between use of aspirin and magnetic resonance imaging‐derived liver fat and fibroinflammation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background The effects of aspirin on hepatic steatosis and fibroinflammation are unclear. The study aimed to examine the association between aspirin use and liver magnetic resonance imaging (MRI)‐derived liver fat and corrected T1 (cT1). Methods We used UK Biobank imaging cohort data.
Qi Feng, Pinelopi Manousou, Chioma N. Izzi‐Engbeaya, Jun Liu, Mark Woodward   +4 more
wiley   +1 more source

A retrospective observational study evaluating the safety and effectiveness of commercially available automated insulin delivery systems in people with type 1 diabetes and gastroparesis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims A retrospective observational cohort study evaluating real‐world outcomes in adults with type 1 diabetes and gastroparesis using automated hybrid closed loop insulin delivery systems (HCL). Materials and Methods All adults with type 1 diabetes and gastroparesis attending King's College Hospital diabetes service and using continuous ...
Rachael J. L. Tan, Anusha Ahuja, Aakanksha Shrestha, Geraldine Gallen, Ben Stotesbury, Yee Cheah, Omar G. Mustafa, Martin B. Whyte, Jonathan Croos, Adam Shooshtarian, Bu' Hussain Hayee, Marietta Stadler   +11 more
wiley   +1 more source

Performance of an automated insulin‐glucagon delivery system versus automated insulin delivery system during challenging inpatient conditions. A single‐blind randomised controlled crossover trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the efficacy and safety of an automated insulin‐glucagon delivery system (AIGD) compared with an automated insulin delivery system (AID). Materials and methods In a 33‐h, randomised, crossover, inpatient study, 13 participants with type 1 diabetes used the DiaCon system in AIGD and AID modes.
Ajenthen G. Ranjan PhD, Christian Laugesen PhD, Dimitri Boiroux PhD, Signe Schmidt PhD, Asbjørn T. Reenberg PhD, Jens Juul Holst DMSc, John B. Jørgensen PhD, Kirsten Nørgaard DMSc   +7 more
wiley   +1 more source

Eye Focusing Ability Can Predict Glycated Hemoglobin Level of Type-1 Diabetes Patients. [PDF]

Health Sci Rep
Okyere BV, Ayobi B, Katumba H, Abokyi S.
europepmc   +1 more source

A case of undetectable glycated hemoglobin (HbA1C) [PDF]

QJM: An International Journal of Medicine, 2018
S N Hegde, M S Srikousthubha, Y J Anupama, null Rathnakar   +3 more
openaire   +2 more sources

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source